BioSpace News Archive

Apellis Pharmaceuticals, Inc. announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria in the United States and European Union, respectively.

William J. Gastle retiring, Martin Marino nominated to become Independent Chairman

Several International Market Authorisations Expected in Q4 Expanding Access to South and Central America and Asia

Acuant , a leading global provider of identity verification, today announced that NeuroLab BI is using Acuant technology to verify the personal data of COVID-19 patients, enabling clinical laboratories to enter complete and accurate patient information into their electronic medical records systems quickly, efficiently an

RxE2 announced today that Lori Doele has joined the company as its new director of business development.

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that Dan Legault, Antibe’s Chief Executive Officer, will present a corporate overview at the upcoming virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2020 at 9:10 am (Eastern Time).

Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presented AbbVie to present a trial-in-progress poster of ABBV-368 in combination with tilsotolimod in recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) Idera also to present at H.C. Wainwright 22nd Annual Global Investment Conference EXTON, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA)

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Dear Fellow Shareholders, This year, we saw the unprecedented need for the collaboration between industry and government in order to meet the challenge of the COVID-19 pandemic. Pluristem

Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company will host a webinar featuring John Vrettos , Ph.D., Senior Principal Scientist and Head of

Humanigen, Inc. (HGEND) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab, today announced that it has commenced an underwritten public offering of 8,000,000 shares of common stock. J.P. Morgan and Jefferies are acting as joint book-running managers for the offering. Humanigen expects